Alazopeptin 是一种分离自多种链霉菌的非核糖体三肽氮杂氨基酸抗生素,具有显著的抗肿瘤、抗菌和抗锥虫活性,对小鼠白血病细胞和 S-180 肿瘤细胞具有细胞毒性,能抑制枯草芽孢杆菌生长,并对布氏锥虫展现出活性,可广泛应用于小鼠白血病、S-180 肿瘤、非洲人类锥虫病和那加那病的相关研究。
产品编号: MS-Z90509 CAS No.: 1397-84-8 分子式: C15H20N6O5 分子量: 364.36
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Alazopeptin 是一种分离自多种链霉菌的非核糖体三肽氮杂氨基酸抗生素,具有显著的抗肿瘤、抗菌和抗锥虫活性,对小鼠白血病细胞和 S-180 肿瘤细胞具有细胞毒性,能抑制枯草芽孢杆菌生长,并对布氏锥虫展现出活性,可广泛应用于小鼠白血病、S-180 肿瘤、非洲人类锥虫病和那加那病的相关研究。

生物实验数据

生物活性 Alazopeptin is a nonribosomal tripeptide aza-amino acid antibiotic isolated from various Streptomyces species that exhibits significant antitumor, antibacterial, and antitrypanosomal activities, is cytotoxic to mouse leukemia cells and S-180 tumor cells, inhibits the growth of Bacillus subtilis, and shows activity against Trypanosoma brucei, and can be widely applied in research related to mouse leukemia, S-180 tumors, human African trypanosomiasis, and nagana.
IC50 & Target

Trypanosoma

 

体外研究
(In Vitro)

Alazopeptin 对 Trypanosoma brucei brucei 菌株 GUTat 3.1 和 Trypanosoma brucei rhodesiense 菌株 STIB900 表现出中等强度的体外抗锥虫活性和低细胞毒性。

Cell Cytotoxicity Assay

Cell Line: Trypanosoma brucei brucei strain and Trypanosoma brucei rhodesiense strain STIB900
Concentration: IC50
Incubation Time: 72 h
Result: Exhibied Trypanosoma brucei brucei strain GUTat 3.1 (IC50=0.51 μg/mL) and Trypanosoma brucei rhodesiense strain STIB900 (IC50=1.21 μg/mL), with low cytotoxicity against human MRC-5 cells (IC50 >9.10 μg/mL).
体内研究
(In Vivo)

Alazopeptin (1.8-57.3 mg/kg;腹腔注射;每日) 可剂量依赖性地延长感染 L-1210 白血病的 CDF1 小鼠的生存期,在每日腹腔注射 57.3 mg/kg 的剂量下,平均应答率最高可达 287%。
Alazopeptin (剂量 4.5-36.4 mg/kg;静脉注射;每日给药;持续 7-10 天) 可剂量依赖性地抑制 dd 小鼠体内 S-180 实体瘤的生长。
Alazopeptin 对 dd 小鼠的艾氏腹水癌未表现出可检测的效果。
Alazopeptin (50 mg/kg;腹腔注射;每日给药;连续 4 天) 无法抑制雌性 ICR 小鼠的 T. b. brucei S427 感染,但可使小鼠的平均存活天数较对照组提升 1.8 倍。

Animal Model: CDF1 mice with Leukemia (~20 g)
Dosage: 57.3 mg/kg/day; 28.7 mg/kg/day; 14.3 mg/kg/day; 7.2 mg/kg/day; 3.6 mg/kg/day; 1.8 mg/kg/day
Administration: i.p.; daily; until death
Result: Achieved a mean survival time (MST) T/C of 23.0/8.0 days, corresponding to an average response of 287% at 57.3 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 16.0/8.0 days (average response 200%) at 28.7 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 14.0/8.0 days (average response 175%) at 14.3 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 13.0/8.0 days (average response 163%) at 7.2 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 11.0/8.0 days (average response 138%) at 3.6 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 8.5/8.0 days (average response 107%) at 1.8 mg/kg/day, with all 6 mice surviving.
Showed better efficacy with daily administration than intermittent administration every 2 days.
Animal Model: dd mice with Sarcoma
Dosage: 36.4 mg/kg/day (days 1-10); 18.2 mg/kg/day (days 1-10); 9.1 mg/kg/day (days 1-10); 4.5 mg/kg/day (days 1-10); 36.4 mg/kg/day (days 5-11); 18.2 mg/kg/day (days 5-11); 9.1 mg/kg/day (days 5-11); 4.5 mg/kg/day (days 5-11)
Administration: i.v.; daily; 10 days (days 1-10); 7 days (days 5-11)
Result: Achieved 100% tumor weight inhibition (tumor weight 0 mg vs control 1401 mg) at 36.4 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 99% tumor weight inhibition (tumor weight 8 mg vs control 1401 mg) at 18.2 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 89% tumor weight inhibition (tumor weight 158 mg vs control 1401 mg) at 9.1 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 21% tumor weight inhibition (tumor weight 1102 mg vs control 1401 mg) at 4.5 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 97% tumor weight inhibition (tumor weight 73 mg vs control 2500 mg) at 36.4 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 90% tumor weight inhibition (tumor weight 259 mg vs control 2500 mg) at 18.2 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 77% tumor weight inhibition (tumor weight 568 mg vs control 2500 mg) at 9.1 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 25% tumor weight inhibition (tumor weight 1870 mg vs control 2500 mg) at 4.5 mg/kg/day (days 5-11), with all 10 mice surviving.
Exhibited marked antitumor activity when treatment started 5 days post-transplantation.

化学信息

分子量 364.36
分子式 C15H20N6O5
CAS No. 1397-84-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础